Sangamo BioSciences | SGMO - Net Income


Sangamo BioSciences reported $-36.13M in Net Income for its fiscal quarter ending in June of 2024.





Net Income Change Date
Alaunos Therapeutics USD -1.16M 417K Sep/2025
Alnylam Pharmaceuticals USD 251.08M 317.36M Sep/2025
Alterity Therapeutics Limited AUD -5.77M 2.26M Jun/2023
Amgen USD 1.33B 1.88B Dec/2025
Bayer EUR -963M 764M Sep/2025
BioCryst Pharmaceuticals USD -88.88M 74.85M Dec/2024
Biogen USD 466.5M 168.3M Sep/2025
BioMarin Pharmaceutical USD -30.74M 271.28M Sep/2025
Cipla INR 6.76B 6.75B Dec/2025
Clal Biotechnology ILS -6.17M 15.56M Dec/2022
Compugen USD -6.98M 360K Sep/2025
CSL USD 497.5M 1.51B Jun/2025
Gilead Sciences USD 2.18B 869M Dec/2025
GlaxoSmithKline GBP 636M 1.38B Dec/2025
Grifols EUR 148.4M 15.76M Sep/2025
Ionis Pharmaceuticals USD -128.61M 252.16M Sep/2025
J&J USD 5.12B 36M Dec/2025
Karyopharm Therapeutics USD -30.78M 1.29M Dec/2024
Merck USD 2.96B 2.82B Dec/2025
Novartis USD 3.93B 96M Sep/2025
Omeros USD -32.23M 23.81M Sep/2024
Pfizer USD -1.65B 5.19B Dec/2025
Roche Holding CHF 5.47B 1.76B Dec/2025
Sangamo BioSciences USD -36.13M 12.96M Jun/2024
Sanofi EUR -801M 3.6B Dec/2025
Sarepta Therapeutics USD -179.95M 376.84M Sep/2025
Tectonic Therapeutic USD -19.04M 940K Sep/2025
Ultragenyx Pharmaceutical USD -180.41M 65.46M Sep/2025
Vertex Pharmaceuticals USD 1.08B 50M Sep/2025